Literature DB >> 20224962

Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.

C Routsi1, M Pratikaki, E Platsouka, C Sotiropoulou, S Nanas, V Markaki, C Vrettou, O Paniara, H Giamarellou, C Roussos.   

Abstract

BACKGROUND: There has been an increasing incidence of carbapenem-resistant Acinetobacter baumannii (CRAB) infections in recent years. The objective of this study was to determine specific risk factors for and outcome of bacteremia due to CRAB isolates among our ICU patients with A. baumannii bacteremia. PATIENTS AND METHODS: Among 96 patients with ICU-acquired A. baumannii bacteremia, 30 patients with CRAB were compared with the remaining 66 with carbapenem-susceptible A. baumannii (CSAB) isolates.
RESULTS: Recent ventilator-associated pneumonia (VAP) due to CRAB (OR 16.74, 95% CI 3.16-88.79, p = 0.001) and a greater number of intravascular devices (OR 3.93, 95% CI 1.9-13.0, p = 0.025) were independently associated with CRAB bacteremia acquisition. Patients with CRAB bacteremia had a lower severity of illness on admission than those with CSAB. Although, by univariate analysis, patients with CRAB were more likely to have had exposure to colistin, carbapenems and linezolid, multivariate analysis did not revealed any significant association. The mortality was not different between patients with CRAB and CSAB bacteremia (43.3 vs. 46.9%, p = 0.740). Severity of organ failure (OR 1.42, 95% CI 1.20-1.67, p = 0.001), and increased white blood cell (WBC) count (OR 1.09, 95% CI 1.01-1.19, p = 0.036), at bacteremia onset were independently associated with mortality.
CONCLUSION: VAP due to CRAB and excess use of intravascular devices are the most important risk factors for CRAB bacteremia in our ICU. Severity of organ failure and WBC count at A. baumannii bacteremia onset are independently associated with mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224962     DOI: 10.1007/s15010-010-0008-1

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  39 in total

1.  Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection.

Authors:  M del Mar Tomas; M Cartelle; S Pertega; A Beceiro; P Llinares; D Canle; F Molina; R Villanueva; J M Cisneros; G Bou
Journal:  Clin Microbiol Infect       Date:  2005-07       Impact factor: 8.067

2.  Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia.

Authors:  Anton Y Peleg; Clare Franklin; Jan M Bell; Denis W Spelman
Journal:  Infect Control Hosp Epidemiol       Date:  2006-06-20       Impact factor: 3.254

Review 3.  Clinical impact and pathogenicity of Acinetobacter.

Authors:  M-L Joly-Guillou
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

Review 4.  Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.

Authors:  L Poirel; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2006-09       Impact factor: 8.067

Review 5.  Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature.

Authors:  M E Falagas; P Kopterides
Journal:  J Hosp Infect       Date:  2006-07-05       Impact factor: 3.926

6.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine.

Authors:  J L Vincent; A de Mendonça; F Cantraine; R Moreno; J Takala; P M Suter; C L Sprung; F Colardyn; S Blecher
Journal:  Crit Care Med       Date:  1998-11       Impact factor: 7.598

7.  Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization.

Authors:  Rebecca H Sunenshine; Marc-Oliver Wright; Lisa L Maragakis; Anthony D Harris; Xiaoyan Song; Joan Hebden; Sara E Cosgrove; Ashley Anderson; Jennifer Carnell; Daniel B Jernigan; David G Kleinbaum; Trish M Perl; Harold C Standiford; Arjun Srinivasan
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

8.  Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance.

Authors:  Stilianos Katsaragakis; Haridimos Markogiannakis; Konstantinos G Toutouzas; Panagiotis Drimousis; Andreas Larentzakis; Eleni-Maria Theodoraki; Dimitrios Theodorou
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

9.  Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes.

Authors:  A Abbo; Y Carmeli; S Navon-Venezia; Y Siegman-Igra; M J Schwaber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

10.  Application of the sequential organ failure assessment (SOFA) score to bacteremic ICU patients.

Authors:  C Routsi; M Pratikaki; C Sotiropoulou; E Platsouka; V Markaki; O Paniara; J-L Vincent; C Roussoss
Journal:  Infection       Date:  2007-07-23       Impact factor: 3.553

View more
  22 in total

1.  Infection control measures to prevent the transmission of nosocomial pathogens: can or should there be an international consensus?

Authors:  C Ruef
Journal:  Infection       Date:  2010-06       Impact factor: 3.553

2.  Morbidity and mortality risk factors in emergency department patients with Acinetobacter baumannii bacteremia.

Authors:  Rui-Xue Sun; Priscilla Song; Joseph Walline; He Wang; Ying-Chun Xu; Hua-Dong Zhu; Xue-Zhong Yu; Jun Xu
Journal:  World J Emerg Med       Date:  2020

3.  Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.

Authors:  M-C Chiang; S-C Kuo; S-J Chen; S-P Yang; Y-T Lee; T-L Chen; C-P Fung
Journal:  Infection       Date:  2011-09-02       Impact factor: 3.553

4.  Control of an Acinetobacter [corrected] baumannii outbreak in a neonatal ICU without suspension of service: a devastating outbreak in Diyarbakir, Turkey.

Authors:  S Hosoglu; M Hascuhadar; E Yasar; S Uslu; B Aldudak
Journal:  Infection       Date:  2011-09-01       Impact factor: 3.553

Review 5.  Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients.

Authors:  Elisabeth Paramythiotou; Christina Routsi
Journal:  World J Crit Care Med       Date:  2016-05-04

6.  Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.

Authors:  John S Esterly; Milena Griffith; Chao Qi; Michael Malczynski; Michael J Postelnick; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

7.  Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology.

Authors:  X Wang; L Zhang; A Sun; X Yang; W Sang; Y Jiang; J Cheng; J Wang; M Zhou; B Chen; J Ouyang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-18       Impact factor: 3.267

8.  Which Multidrug-Resitant Bacteria are Emerging in Patients with Hematological Malignancies?: One-Year Report.

Authors:  Habip Gedik; Funda Şimşek; Taner Yıldırmak; Arzu Kantürk; Demet Aydın; Naciye Demirel; Osman Yokuş; Deniz Arıca
Journal:  Indian J Hematol Blood Transfus       Date:  2014-05-14       Impact factor: 0.900

9.  Pathogenicity of clinical Acinetobacter baumannii isolates in a Galleria mellonella host model according to bla(OXA-40) gene and epidemiological outbreak status.

Authors:  John S Esterly; Milena M McLaughlin; Michael Malczynski; Chao Qi; Teresa R Zembower; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

10.  Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients.

Authors:  Christina Routsi; Maria Pratikaki; Evangelia Platsouka; Christina Sotiropoulou; Vasileios Papas; Theodoros Pitsiolis; Athanassios Tsakris; Serafeim Nanas; Charis Roussos
Journal:  Intensive Care Med       Date:  2013-04-20       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.